Astrazeneca to ‘upgrade’ US listing in latest blow to London Stock ExchangeAstrazeneca has paused plans for a Cambridge siteAstrazeneca has laid out plans aimed at “upgrading” its US listing in the latest blow to the London Stock Exchange. But the company has recommitted to the UK, adding that it would continue to be listed, headquartered in and tax resident in Britain. The announcement also puts to bed rumours that the pharma firm had been plotting to delist from London altogether. Read more Reeves urged to give stamp duty holiday for fresh stock exchange listings“I think there is probably relief that it’s not pursuing a primary listing in New York, but the decision is hardly a ringing endorsement of London. In July, the company unveiled plans to invest as much as $50bn in manufacturing and R&D in the US over the next five years.